SEC Form SC 13G filed by Gossamer Bio Inc.
$GOSS
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/23/2026 | Overweight → Neutral | Cantor Fitzgerald | |
| 2/24/2026 | $1.00 | Outperform → Neutral | Wedbush |
| 2/24/2026 | $0.30 | Overweight → Equal Weight | Barclays |
| 2/24/2026 | $1.00 | Outperform → Market Perform | Leerink Partners |
| 1/28/2026 | $9.00 | Overweight | Barclays |
| 9/10/2025 | $9.00 | Neutral → Buy | UBS |
| 7/14/2025 | $11.00 | Sector Outperform | Scotiabank |
| 6/25/2024 | $9.00 | Outperform | Oppenheimer |
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
4 - Gossamer Bio, Inc. (0001728117) (Issuer)
8-K - Gossamer Bio, Inc. (0001728117) (Filer)
PRE 14A - Gossamer Bio, Inc. (0001728117) (Filer)
DEFA14A - Gossamer Bio, Inc. (0001728117) (Filer)
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has extended the early tender date (as extended, the "Extended Early Tender Date") until 5:00 p.m., New York City time, on June 2, 2026 with respect to its previously announced exchange offer (the "Exchange Offer") and consent solicitation (the "Consent Solicitation") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has commenced an exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to 317,647,058 shares of its common stock (th
Cantor Fitzgerald downgraded Gossamer Bio from Overweight to Neutral
Wedbush downgraded Gossamer Bio from Outperform to Neutral and set a new price target of $1.00
Barclays downgraded Gossamer Bio from Overweight to Equal Weight and set a new price target of $0.30
Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
SC 13G/A - Gossamer Bio, Inc. (0001728117) (Subject)
Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the early tender results of its previously announced exchange offer (the "Exchange Offer") to exchange any and all of its 5.00% Convertible Senior Notes due 2027 (the "Existing Convertible Notes") for a pro rata portion of (i) up to $72.0 million in aggregate principal amount of its new 7.50% Convertible Senior Secured First Lien Notes due 2030 (the "New Convertible Notes"), (ii) up to
- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes - - Gossamer Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 5.00% Convertible Senior Notes Due 2027 - - Cash, cash equivalents and marketable securities totaled $99 million as of March 31 - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with in
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2026 financial results on Monday, May 18, 2026. In connection with the earnings release, Gossamer's management team will host a live conference call and webcast at 8:00 a.m. ET on Monday, May 18, 2026, to discuss the Company's financial results and provide a corporate update. Domestic Dial-in Number: 1-800-715-9871 International Dial-in Number: 1-646-307-1963
- Mr. Smith is a recognized leader in the commercialization of PAH products, most recently leading sotatercept US pre-launch activities at Merck - - Previously, Mr. Smith led US sales operations for Actelion - Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of Bob Smith as its Chief Commercial Officer. "We are proud to welcome Bob Smith to the Gossamer team and his 30 years of expertise at this critical time in our company's history," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio.
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors. "Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quise
Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that Rainer Zimmermann, MD, has joined the Company as Vice President of Medical Affairs. Dr. Zimmermann brings more than 23 years of experience within the PAH/PH space, most recently having served as the Global Medical Lead, Medical Affairs, Pulmonary Hypertension, at Johnson & Johnson Innovative Medicine. In this role, he partnered with the development and commercial teams to lead pre-launch and launch activities of several approved PAH products, including Uptravi® (selixpag),